Chronic Pain and Transcranial Direct Current Stimulation in Clinical Settings

July 10, 2023 updated by: Guillaume Léonard, Université de Sherbrooke

Reduce Chronic Pain With Transcranial Direct Current Stimulation in Clinical Settings

Physical exercises and transcranial direct current stimulation (tDCS) are both known to reduce chronic pain in structured laboratory studies. The aim of this study is to assess the efficacy of this combined treatment in clinical settings.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Chronic pain patients who are going to the physiotherapy clinic to receive tDCS treatment sessions are evaluated in order to assess the efficacy of tDCS in clinical settings. Physiotherapists prescribe physical exercises adapted to the patients conditions. Patients performed their physical exercises every time they received a tDCS treatment, but were also recommended to continue their physical exercises program at home after completion of physiotherapy visits.

Concerning tDCS treatment, patients were encouraged to receive 1 tDCS session per day for 5 consecutive days.

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Canada
    • Quebec
      • Sherbrooke, Quebec, Canada, J1L 0H8
        • Recruiting
        • Physio-Atlas
        • Contact:
          • Antoine Laramé, M.Sc.
          • Phone Number: 819-562-0868

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

All patients that received tDCS sessions in clinical settings

Description

Inclusion Criteria:

  • To have chronic pain

Exclusion Criteria:

  • Contraindication to tDCS

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in McGill pain Questionnaire
Time Frame: Baseline, 1 week, 1 month
qualitative and quantitative aspects of pain
Baseline, 1 week, 1 month
Change in Brief Pain Inventory
Time Frame: Baseline, 1 week, 1 month
Physical Function
Baseline, 1 week, 1 month
Change in Tampa Questionnaire
Time Frame: Baseline, 1 week, 1 month
Kinesiophobia
Baseline, 1 week, 1 month
Change in Beck Depression Inventory
Time Frame: Baseline, 1 week, 1 month
Depression
Baseline, 1 week, 1 month
Change in Patient global impression of change
Time Frame: 1 week, 1 month
Impression of change
1 week, 1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of sessions received
Time Frame: Through study completion, an average of 5 days
Feasibility; did the patients received all their tDCS sessions in 5 days (1 per day)
Through study completion, an average of 5 days
Side effect
Time Frame: Through study completion, an average of 5 days
Side effect reported by the patients (headache, dizziness, fatigue, nausea, redness, tingling)
Through study completion, an average of 5 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Université de Sherbrooke

Investigators

  • Principal Investigator: Guillaume Léonard, PhD, Université de Sherbrooke

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 4, 2021

Primary Completion (Actual)

February 4, 2021

Study Completion (Estimated)

December 1, 2023

Study Registration Dates

First Submitted

January 15, 2021

First Submitted That Met QC Criteria

January 26, 2021

First Posted (Actual)

January 27, 2021

Study Record Updates

Last Update Posted (Actual)

July 12, 2023

Last Update Submitted That Met QC Criteria

July 10, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020-3273-PA

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Pain

Clinical Trials on transcranial direct current stimulation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe